Skip to content

To Assess the Safety and Effectiveness of Hyruan ONE Versus a Comparator for the Treatment of Knee Osteoarthritis in Europe

A Prospective, Active Controlled, Randomised, Parallel Group, Double Blind, Multicentre Study to Assess the Safety and Effectiveness of Hyruan ONE Versus a Comparator for the Treatment of Knee Osteoarthritis in Europe

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04732793
Enrollment
284
Registered
2021-02-01
Start date
2021-02-03
Completion date
2021-12-07
Last updated
2022-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis (OA) of the Knee

Brief summary

To Assess the Safety and Effectiveness of Hyruan ONE versus a Comparator for the Treatment of Knee Osteoarthritis in Europe

Interventions

DEVICEHyruan ONE®

For use as a symptomatic treatment of osteoarthritis (OA) of the knee

For use as a symptomatic treatment of osteoarthritis (OA) of the knee

Sponsors

LG Chem
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Subject is ≥40 years old. 2. Subject has radiographic evidence of mild-to-moderate OA (Kellgren Lawrence Scale grade II III) in one or both knees. Radiographs to be taken within 12 months prior to the Screening visit. 3. Subject has OA pain in the target knee despite conservative physical treatments and/or analgesics.

Exclusion criteria

1. Subject has rheumatoid arthritis or other inflammatory metabolic arthritis. 2. Subject has a documented history of hypersensitivity to HA. 3. Subject has a documented infection or severe inflammation of the target knee joint. 4. Subject has a skin disease in the area of the injection site. 5. Subject has a clinically apparently tense effusion of the target knee on examination determined by either a positive bulge sign or positive ballottement of the patella (patellar tap). 6. Subject has chronic pain requiring chronic ongoing analgesic therapy that confounds the measurement of pain in the target knee.

Design outcomes

Primary

MeasureTime frameDescription
The change in the WOMAC(Western Ontario and McMaster Universities Osteoarthritis Index) Likert pain subscorefrom Baseline to 13 weeks post injection.The WOMAC Likert Index measures 3 separate dimensions: pain, stiffness, and function. The subject will self assess the level of pain in the target knee joint for the prior 48 hours (5 questions), the level of difficulty of performing daily activities (17 questions), and the level of stiffness (2 questions) using the WOMAC Likert Questionnaire (24 total questions; 4 points/question). Each item of the WOMAC Likert Index will be assessed using the scale of 0=none, 1=a little, 2=moderate, 3=severe, 4=very severe. The aggregate total score that can result for each scale is as follows: Pain = 0-20 Stiffness = 0-8 Physical function = 0-68.

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026